The Office of Cancer Clinical Proteomics Research (OCCPR) at the National Cancer Institute (NCI) supports the advancement of proteomic and proteogenomic science to deepen our understanding of cancer and enhance clinical trials. By investigating the molecular foundations of cancer, identifying targets for precision oncology, and providing data and resources, OCCPR aims to improve cancer diagnosis, treatment, and outcomes. Our efforts are led by the Clinical Proteomic Tumor Analysis Consortium (CPTAC) and other key initiatives. OCCPR also spearheads partnerships with federal and international agencies, as well as organizations and institutions worldwide.
Our Mission
Our mission is to advance cancer research through proteomic and proteogenomic science by turning these insights into new treatment options. To expedite advancements in cancer care, we foster collaboration and resource sharing.
Learn more about OCCPR’s research activities.